Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.64 |
| ▸ | IL1RN | P18510 | 1/20 | 0.64 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789469 | 0.96 | KEAP1 (0.64) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL7171852 | 0.88 | GAA (0.58) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL28538527 | 0.85 | WDR5 (0.73) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL3791521 | 0.85 | PGR (0.81) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL3762452 | 0.85 | PGR (0.74) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL29562342 | 0.84 | PGR (0.72) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL29985647 | 0.83 | GAA (0.65) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL2133710 | 0.82 | CES1 (0.81) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL21462374 | 0.82 | PGR (0.57) | KEAP1IL1RNERAP1PGRALDH1A1 | |
| SCHEMBL6478779 | 0.81 | KEAP1 (0.60) | KEAP1IL1RNERAP1PGRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940798-B2 | Compounds useful for treating and/or preventing disease-associated bone loss | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-01-27 | — | — | US | claimed |
| US-20130165523-A1 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (FR) | 2013-06-27 | — | — | US | claimed |
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2019197659-A1 | NEW INHIBITORS OF BONE RESORPTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553061-A1 | NEW INHIBITORS OF BONE RESORPTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-16 | — | — | EP | disclosed |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| EP-2367798-B1 | PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV NORTHWESTERN (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2367798-B1 | PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV NORTHWESTERN (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-8940798-B2 | Compounds useful for treating and/or preventing disease-associated bone loss | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-01-27 | — | — | US | disclosed |
| US-20130165523-A1 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (FR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165523-A1 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (FR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165523-A1 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (FR) | 2013-06-27 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165523-A1 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | SOST, COL2A1, GLA | KEAP1 596/4885IL1RN 1054/4885ERAP1 707/4885 |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | SMN1; SMN2, SOD1, NLN | KEAP1 189/4885IL1RN 2912/4885ERAP1 1346/4885 |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | KEAP1 189/4885IL1RN 2912/4885ERAP1 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.